Knight Therapeutics Inc. (TSX:GUD)

Knight Therapeutics Revenue

Knight Therapeutics had revenue of 148.44M CAD in the quarter ending March 31, 2026, with 68.54% growth. This brings the company's revenue in the last twelve months to 510.45M, up 36.93% year-over-year. In the year 2025, Knight Therapeutics had annual revenue of 450.09M with 21.22% growth.

• Revenue (ttm): 510.45M
• Revenue Growth: +36.93%
• P/S Ratio: 1.61
• Revenue / Employee: 615.00K
• Employees: 830
• Market Cap: 819.80M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	450.09M	78.78M	21.22%
Dec 31, 2024	371.30M	43.11M	13.13%
Dec 31, 2023	328.20M	34.64M	11.80%
Dec 31, 2022	293.56M	50.09M	20.57%
Dec 31, 2021	243.48M	43.96M	22.03%
Dec 31, 2020	199.52M	152.06M	320.39%
Dec 31, 2019	47.46M	34.96M	279.69%
Dec 31, 2018	12.50M	3.87M	44.78%
Dec 31, 2017	8.63M	2.69M	45.35%
Dec 31, 2016	5.94M	4.90M	472.81%
Dec 31, 2015	1.04M	672.00K	184.11%
Dec 31, 2014	365.00K	-	-

Data Source: Fiscal.ai Last updated: May 7, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 23, 2026

Data Sources Report a data error